AllSci News
FDA Resumes Review of Capricor's Deramiocel for Duchenne Muscular Dystrophy Cardiomyopathy
The US FDA has resumed review of a Biologics License Application (BLA) from Capricor Therapeutics for Deramiocel (CAP-1002), an allogeneic...
Jacobio receives USD 100m upfront from AstraZeneca for pan-KRAS inhibitor JAB-23E73 license deal
Jacobio Pharma confirmed receipt of a USD 100 million upfront payment from AstraZeneca under the license and collaboration agreement for JAB-23E73, a...
VeonGen Therapeutics' VG801 gene therapy shows early promise in ABCA4-associated Stargardt disease trial
VeonGen Therapeutics, a clinical-stage company based in Munich, Germany, announced preliminary data from its ongoing Phase I/II first-in-human trial of...
UCB's bimekizumab beats risankizumab in first head-to-head psoriatic arthritis biologic trial
Brussels-based UCB announced topline results from BE BOLD, a Phase III trial comparing bimekizumab (BIMZELX) with risankizumab (SKYRIZI) in adults with...
Novartis' iptacopan slows kidney function decline by 49% in Phase III IgA nephropathy trial
Novartis (SWX: NOVN) reported final two-year results from the Phase III APPLAUSE-IgAN study showing that iptacopan (Fabhalta) slowed kidney function decline...
Argo Biopharma Secures FDA Fast Track Designation for siRNA Therapy BW-20805 Targeting Hereditary Angioedema
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company headquartered in Shanghai and New York, announced that the U.S....
MetaVia secures global patent portfolio for DA-1726 dual agonist obesity therapy through 2041
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company headquartered in the US, announced on February 13, 2026, that it has assembled a...
PRISM BioLab and Receptor.AI collaborate on AI-guided drug discovery targeting protein-protein interactions
PRISM BioLab and Receptor.AI Enter Drug Discovery Collaboration to Target Protein-Protein Interactions with AI-Guided Platform
Sanofi acquires global rights to rovadicitinib from Sino Biopharmaceutical in up to USD 1.53b deal
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of Hong Kong-listed Sino Biopharmaceutical Limited (HKEX: 1177), has entered into an...
Dizal's sunvozertinib achieves 81% response rate as first-line therapy in EGFR PACC-mutant NSCLC
Dizal (SSE:688192) reported new clinical data for sunvozertinib NSCLC at the 2026 European Lung Cancer Congress in Copenhagen, showing an 81.3% objective...
Tempus AI and Daiichi Sankyo collaborate on AI-driven biomarker discovery for antibody drug conjugate
Tempus AI and Daiichi Sankyo have entered a strategic collaboration to apply artificial intelligence and real-world data analytics to the clinical...
Kyowa Kirin and Amgen terminate rocatinlimab trials over malignancy signal in atopic dermatitis
Japan-based Kyowa Kirin Co., Ltd. and partner Amgen have discontinued all ongoing clinical trials for rocatinlimab, an anti-OX40 monoclonal antibody that...
Cbio advances novoleucel T-cell therapy into first-in-human trial for recurrent cervical cancer
Copenhagen-based Cbio A/S has received European regulatory clearance to initiate a first-in-human Phase I/IIa clinical trial of novoleucel, a T-cell therapy...
PepGen faces FDA partial clinical hold on PGN-EDODM1 trial for myotonic dystrophy type 1
PepGen Inc. (Nasdaq: PEPG) announced that the U.S. Food and Drug Administration has placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple...
VST BIO Corporation Closes Series A Financing With $45M Total Investment to Advance Stroke Therapy
VST BIO Corporation, a San Diego-headquartered biotechnology company developing therapeutics for acute ischemic stroke, has closed a Series A financing...
The AllSci Brief
Systematic R&D and deal news. Daily.